Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

K-Ras prenylation as a potential anticancer target

Open access
Baranyi, Marcell, Buday, László, Hegedűs, Balázs · 2020 · Cancer and Metastasis Reviews

Abstract

KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies. Therefore, the development of targeting strategies against mutant KRAS is urgently needed. One potential strategy involves disruption of K-Ras membrane localization, which is necessary for its proper function. In this review, we summarize the current data about the importance of membrane-anchorage of K-Ras and provide a critical evaluation of this targeting paradigm focusing mainly on prenylation inhibition. Additionally, we performed a RAS mutation-specific analysis of prenylation-related drug sensitivity data from a publicly available database (https://depmap.org/repurposing/) of three classes of prenylation inhibitors: statins, N-bisphosphonates, and farnesyl-transferase inhibitors. We observed significant differences in sensitivity to N-bisphosphonates and farnesyl-transferase inhibitors depending on KRAS mutational status and tissue of origin. These observations emphasize the importance of factors affecting efficacy of prenylation inhibition, like distinct features of different KRAS mutations, tissue-specific mutational patterns, K-Ras turnover, and changes in regulation of prenylation process. Finally, we enlist the factors that might be responsible for the large discrepancy between the outcomes in preclinical and clinical studies including methodological pitfalls, the incomplete understanding of K-Ras protein turnover, and the variation of KRAS dependency in KRAS mutant tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10555-020-09902-w

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Most common oncogenic mutations and posttranslational modification sites of the HVR regions in the Ras proteins
Fig. 1 Most common oncogenic mutations and posttranslational modification sites of the HVR regions in the Ras proteinsCC BY · PubMed Central
Fig. 2 Effect of prenylation inhibition on receptor tyrosine kinase (RTK) pathway. Distinct classes of prenylation inhibitors act on different levels of the mevalonate pathway. Statins and N-bisphosphonates shut down farnesyl-PP synthesis, leading to—besides inhibition of prenylation—depletion of dolichols and cholesterol. Dolichols are involved in N-glycolysation that is essential for proper ligand binding of certain RTKs, like EGFR. Cholesterol is a major compound of lipid rafts, specific microdomains of the plasma membrane functioning as signalization hubs in many major signaling pathways (e.g., EGFR and HER2). Prenylation inhibition concerns many major cellular process, like proliferation, survival, migration (K-Ras, Rheb Rho), vesicular transport, and autophagy (Rab). Interference with this metabolic pathway likely leads to pleiotropic effects
Fig. 2 Effect of prenylation inhibition on receptor tyrosine kinase (RTK) pathway. Distinct classes of prenylation inhibitors act on different levels of the mevalonate pathway. Statins and N-bisphosphonates shut down farnesyl-PP synthesis, leading to—besides inhibition of prenylation—depletion of dolichols and cholesterol. Dolichols are involved in N-glycolysation that is essential for proper ligand binding of certain RTKs, like EGFR. Cholesterol is a major compound of lipid rafts, specific microdomains of the plasma membrane functioning as signalization hubs in many major signaling pathways (e.g., EGFR and HER2). Prenylation inhibition concerns many major cellular process, like proliferation, survival, migration (K-Ras, Rheb Rho), vesicular transport, and autophagy (Rab). Interference with this metabolic pathway likely leads to pleiotropic effectsCC BY · PubMed Central
Fig. 3 Drug sensitivity values from PRISM repurposing primary screen of all cell lines independent of tissue of origins. Efficacy of statins, nitrogen-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed by analyzing the open access data from [52]. Drugs included for the analyses are listed in Table 2. KRAS mutant cell lines were more resistant to statins (RAS WT mean − 0.123, SEM 0.024; KRAS MUT mean – 0.176, SEM 0.040), while the opposite can be observed in response to N-bisphosphonate treatment (RAS WT mean – 0.124, SEM 0.010; KRAS MUT mean − 0.176, SEM 0.022). Statistical significance was established in p < 0.05, using two-tailed t test. Number of cell lines included in the analyses RAS WT n ~ 390; KRAS MUT n ~ 103 (there is a small variation between the numbers of cell lines with available data for the distinct drugs)
Fig. 3 Drug sensitivity values from PRISM repurposing primary screen of all cell lines independent of tissue of origins. Efficacy of statins, nitrogen-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed by analyzing the open access data from [52]. Drugs included for the analyses are listed in Table 2. KRAS mutant cell lines were more resistant to statins (RAS WT mean − 0.123, SEM 0.024; KRAS MUT mean – 0.176, SEM 0.040), while the opposite can be observed in response to N-bisphosphonate treatment (RAS WT mean – 0.124, SEM 0.010; KRAS MUT mean − 0.176, SEM 0.022). Statistical significance was established in p < 0.05, using two-tailed t test. Number of cell lines included in the analyses RAS WT n ~ 390; KRAS MUT n ~ 103 (there is a small variation between the numbers of cell lines with available data for the distinct drugs)CC BY · PubMed Central
Fig. 4 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of statins, nitrogene-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed. List of drugs included for the analyses are listed in Table 2. Interestingly, statistically significant difference could only be observed in lung cancer cell lines treated with FTis (RAS WT mean – 0.021, SEM 0.076; KRAS MUT mean – 0.385, SEM 0.117). Note the opposite trends in sensitivity between N-bisphosphonate- and FTi-treated colorectal and lung cancer cells. Statistical significance was established in p < 0.05, using two-tailed t test. n analysis was performed using the open access data of [52]. Number of cell lines included in the analyses for colorectal cancer cell lines: RAS WT n ~ 10; KRAS MUT n ~ 20; for lung adenocarcinomas: RAS WT n ~ 28; KRAS MUT n ~ 18. There is a small variation between the number of cell lines with available data for the distinct drugs
Fig. 4 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of statins, nitrogene-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed. List of drugs included for the analyses are listed in Table 2. Interestingly, statistically significant difference could only be observed in lung cancer cell lines treated with FTis (RAS WT mean – 0.021, SEM 0.076; KRAS MUT mean – 0.385, SEM 0.117). Note the opposite trends in sensitivity between N-bisphosphonate- and FTi-treated colorectal and lung cancer cells. Statistical significance was established in p < 0.05, using two-tailed t test. n analysis was performed using the open access data of [52]. Number of cell lines included in the analyses for colorectal cancer cell lines: RAS WT n ~ 10; KRAS MUT n ~ 20; for lung adenocarcinomas: RAS WT n ~ 28; KRAS MUT n ~ 18. There is a small variation between the number of cell lines with available data for the distinct drugsCC BY · PubMed Central
Fig. 5 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of farnesyl-transferase inhibitors (tipifarnib and lonafarnib) on HRAS mutant cells versus RAS wild-type cell lines is presented. A strong tendency was observed, HRAS mutant cells were more sensitive to FTi treatment than RAS wild-type cells (RAS WT mean – 0.178, SEM 0.026; HRAS MUT mean – 0.554, SEM 0.243). p value was calculated using two-tailed t test. The open access data of [52] was used for the analysis. Number of cell lines included in the analyses: RAS WT n = 396; HRAS MUT n = 7 (created by Graphpad Prism 5 software)
Fig. 5 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of farnesyl-transferase inhibitors (tipifarnib and lonafarnib) on HRAS mutant cells versus RAS wild-type cell lines is presented. A strong tendency was observed, HRAS mutant cells were more sensitive to FTi treatment than RAS wild-type cells (RAS WT mean – 0.178, SEM 0.026; HRAS MUT mean – 0.554, SEM 0.243). p value was calculated using two-tailed t test. The open access data of [52] was used for the analysis. Number of cell lines included in the analyses: RAS WT n = 396; HRAS MUT n = 7 (created by Graphpad Prism 5 software)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 64

Metadata

Authors
Baranyi, M., Buday, L., & Hegedűs, B.
Affiliations
  • Semmelweis University (HU)
  • Institute of Molecular Life Sciences (HU)
  • Ruhrlandklinik (DE)
Corresponding author
Hegedűs, Balázs
Venue
Cancer and Metastasis Reviews
Published
2020-06-10
Volume
39
Issue
4
Pages
1127-1141
ISSN
  • 0167-7659 (ISSN-L)
  • 1573-7233
OpenAlex
W3033488157
Cited by
62
References
94
Citations by year
2026: 10 · 2025: 15 · 2024: 13 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4
FWCI
0.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer and Metastasis Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Funders
Hungarian National Research, Development and Innovation Office (NVKP-16-1-2016-0020)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
KRAS, membrane anchorage, KRAS mutation, farnesyltransferase inhibitors, statins, drug repurposing, anticancer drug targets, KRAS-mutant tumors
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Protein Processing, Post-Translational, Genes, ras, Proto-Oncogene Proteins p21(ras), Prenylation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: K-Ras prenylation as a potential anticancer target. https://app.cochat.ai/papers/10.1007/s10555-020-09902-w
The paper
Baranyi, M., Buday, L., & Hegedűs, B. (2020). K-Ras prenylation as a potential anticancer target. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-020-09902-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.